Broadest Immune Response from Nasal Spray Vaccine, NIH-Funded Study Finds

(The following is an excerpt from an article published by the National Institute of Allergy and Infectious Diseases on August 16, 2011. Featured in the article is Dr. Daniel Hoft, who collaborates with EpiVax on vaccine research. In addition, Dr. Hoft gave a lecture titled “Romana’s Sign of the Times: Molecular Approaches for Protective T. cruzi Vaccines” during iCubed’s 2010 Vaccine Renaissance Conference.)

‘Children younger than 3 years old receive the same protective antibody response from the recommended two doses of licensed seasonal influenza vaccines regardless of whether the two doses are injected by needle, inhaled through a nasal spray or provided through one dose of each in any order, according to researchers funded by the National Institutes of Health. Doctors usually give young children two matching vaccines, and one goal of the study was to determine whether giving two different types of vaccines works just as well.’ (Read the full article here)